Integrative gene set analysis: application to platinum pharmacogenomics.

Area of Science:

• Genomics
• Cancer Biology
• Pharmacogenomics

Background:

• Complex phenotypes and drug responses involve multiple genes and data types, including genetic variation, mRNA, DNA methylation, and copy number variation.
• Understanding gene set (GS) interactions is crucial for deciphering complex traits and predicting therapeutic outcomes.

Purpose of the Study:

• To develop and apply an integrative gene set analysis approach to uncover novel genetic factors influencing response to chemotherapy.
• To investigate the role of gene sets in cisplatin (CDDP) pharmacogenomics using lymphoblastoid cell lines.

Main Methods:

• Developed an integrative gene set analysis strategy combining multiple genomic data types.
• Applied the approach to genome-wide SNP and mRNA expression data from lymphoblastoid cell lines treated with cisplatin.
• Validated candidate genes (LMNB1, CENPF) using siRNA knockdown experiments in cancer cell lines.

Main Results:

• The integrative gene set analysis identified RNA binding and cytoskeletal part gene sets as relevant to CDDP response.
• Functional validation confirmed that knockdown of LMNB1 and CENPF confers resistance to cisplatin in multiple cancer cell lines.
• This highlights the utility of integrative analysis for identifying novel therapeutic targets.

Conclusions:

• Integrative gene set analysis is a powerful strategy for dissecting complex genetic architectures underlying drug response.
• Identified LMNB1 and CENPF as novel genes associated with cisplatin resistance, offering potential for personalized cancer therapy.
• The study advances the goal of tailored cancer treatment by uncovering key molecular players in chemotherapy response.